Inhaler Operability and Patient Satisfaction Regarding Genuair® and Respimat® Inhalers for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Study

Ohbayashi, Hiroyuki; Kudo, Sahori; Ishikawa, Masatake

doi:10.1007/s41030-017-0038-2

Cited by 7 publications

(9 citation statements)

References 16 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of overall device use errors with SMIs was computed based on the reported proportion of patients who made at least one device use error during the inhalation process. For studies that did not provide an overall error rate, [41][42][43] it was inferred based on the reported inhalation step with the highest frequency of error. For one study, 44 the overall device use error was considered the same as the reported error rate from the single inhalation step for which data were provided.…”

Section: Discussionmentioning

confidence: 99%

“…21 Regardless of device type, mishandling has been associated with poor health outcomes, more frequent exacerbations, increase in hospitalizations, and higher health resource utilization. [21][22][23] Thus, the economic 41 , Molimard et al 22 , Liang et al 48 , and Ding et al 39 . The rest of studies were Ngo et al 46 , Bournival et al 47 , de Oliveira et al 40 , Windisch et al 45 , Takaku et al 49 , Chorao et al 42 , and Asakura et al 43 .…”

Section: Discussionmentioning

confidence: 99%

“…Among these articles, 33 did not provide information on device use errors, resulting in a total of 12 publications that were included in this meta-analysis. 22,[39][40][41][42][43][44][45][46][47][48][49] Since this study involved reviewing aggregate level secondary data published in publicly available studies and there was no access to primary patient-level data, protocol approval by the Institutional Review Board and Ethical Committee was waived.…”

Section: Search Strategymentioning

confidence: 99%

“…Significant heterogeneity was observed across the 12 studies included in our meta-analysis (I 2 ¼ 92.8%; test for heterogeneity: Q(df ¼ 11): 273.6, p < 0.001). Sensitivity analysis revealed that the pooled effect size was altered with the removal of five studies 22,39,41,44,49 (Figure 4). The resulting overall effect size was 57.5% (95% CI: 21.2-93.9) across the five studies relative to 59.8% (95% CI: 51.3-68.4) for the remaining seven studies.…”

Section: Heterogeneity and Sensitivity Analysismentioning

confidence: 99%

See 3 more Smart Citations

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Inhaled bronchodilators are the cornerstone of treatment for chronic obstructive pulmonary disease (COPD). Soft mist inhalers (SMIs) are devices that deliver bronchodilators. Although correct device use is paramount to successful medication delivery, patient errors are common. This global systematic literature review and meta-analysis examined device use errors with SMIs among patients with obstructive lung diseases. PubMed, EMBASE, PsycINFO, Cochrane, and Google Scholar were searched to identify studies published between 2010 and 2019 that met the following inclusion criteria: (a) English language; (b) a diagnosis of COPD, bronchitis, or emphysema; and (c) reported device use errors among adults receiving long-acting bronchodilator treatment with Respimat® SMI (i.e. Spiriva®, Stiolto®, Spiolto®, and Striverdi®). Descriptive statistics examined sociodemographics, clinical characteristics, and device use errors. Meta-analysis techniques were employed with random-effects models to generate pooled mean effect sizes and 95% confidence intervals (CIs) for overall and step-by-step errors. The I 2 statistic measured heterogeneity. Twelve studies ( n = 1288 patients) were included in this meta-analysis. Eighty-eight percent of patients had COPD, and most had moderate/very severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease spirometric stages II to IV). Aggregate results revealed that 58.9% (95% CI: 42.4–75.5; I 2 = 92.8%) of patients made ≥1 device use errors. Among 11 studies with step-by-step data, the most common errors were failure to (1) exhale completely and away from the device (47.8% (95% CI: 33.6–62.0)); (2) hold breath for up to 10 seconds (30.6% (95% CI: 17.5–43.7)); (3) take a slow, deep breath while pressing the dose release button (27.9% (95% CI: 14.5–41.2)); (4) hold the inhaler upright (22.6% (95% CI: 6.2–39.0)); and (5) turn the base toward the arrows until it clicked (17.6% (95% CI: 3.0–32.2)). Device use errors occurred in about 6 of 10 patients who used SMIs. An individualized approach to inhalation device selection and ongoing training and monitoring of device use are important in optimizing bronchodilator treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Search Strategymentioning

confidence: 99%

Section: Heterogeneity and Sensitivity Analysismentioning

confidence: 99%

See 2 more Smart Citations

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…3,[26][27][28] However, these errors can be addressed through proper training and demonstration. [29][30][31][32] Common device-handling errors include 4,26,27,32,33 :…”

Section: Importance Of Proper Inhaler Techniquementioning

confidence: 99%

Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease

Dhand

Cavanaugh

Skolnik³

2018

CCJM

View full text Add to dashboard Cite

Comparison of User Satisfaction and Preference with Inhalant Devices Between a Pressurized Metered-Dose Inhaler and Ellipta in Stable Asthma Patients: A Randomized, Crossover Study

Ohbayashi¹,

Asano²,

Kudo³

et al. 2021

Pulm Ther

Self Cite

View full text Add to dashboard Cite

Introduction Inhalation therapy involves two types of adherence: adherence to the drug and adherence to the procedures for the inhalation device. User satisfaction and preference are key factors for maintaining good adherence of both types, and they should be evaluated based on three conditions being well maintained: asthma control level (ACL), adherence, and adequate device operability during usage duration. We compared user satisfaction and preference between a pressurized metered-dose inhaler (pMDI) and a dry powder inhaler (Ellipta), while maintaining the three conditions during usage in stable asthma patients. Methods In this open-label, randomized, two-way crossover study, patients with stable asthma [Asthma Control Questionnaire (ACQ) scores < 0.75] were classified into a 20–64-year age group (G1) and a ≥ 65-year age group (G2) and randomly assigned to either a formoterol/fluticasone combination (FFC) as the pMDI group or a vilanterol/fluticasone combination (VFC) as the Ellipta group. Satisfaction and preference levels were evaluated at week 4. ACL was measured using the ACQ and Japan Asthma Control Survey questionnaires at weeks 0 and 4. Device operability and respiratory resistance were also examined. Results Forty-four patients (23 G1, age 45.8 ± 1.9 years; 21 G2, 74.1 ± 1.3 years) were enrolled and maintained good ACL during the study. Adherence to FFC pMDI and VFC Ellipta was > 97% in all groups. Device operability did not differ significantly between FFC pMDI and VFC Ellipta in the G1 (p = 0.189) or G2 (p = 0.506) group. Overall satisfaction was marginally higher with the FFC pMDI than with the VFC Ellipta in G2 (p = 0.012) but non-significantly different in G1 (p = 0.733). Factors affecting overall satisfaction in G2 were difference of inhalation device and body mass index. Respiratory resistance did not change significantly over the study in G2. Conclusion Based on maintaining good ACL, adherence, and device operability, FFC pMDI showed significantly higher satisfaction and preference levels than VFC Ellipta in elderly persons. Trial Registration Japan Registry of Clinical Trials identifier, jRCTs041180001 (registered 21 August 2018).

show abstract

Inhaler Operability and Patient Satisfaction Regarding Genuair® and Respimat® Inhalers for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Study

Abstract: Introduction: Tiotropium via the Respimat

Cited by 7 publications

References 16 publications

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis

Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease

Comparison of User Satisfaction and Preference with Inhalant Devices Between a Pressurized Metered-Dose Inhaler and Ellipta in Stable Asthma Patients: A Randomized, Crossover Study

Contact Info

Product

Resources

About